Date published: 2025-10-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

C12orf59_D630042F21Rik Inhibitors

Chemical inhibitors of C12orf59 can impact its activity through various molecular pathways. Palbociclib targets CDK4/6, key regulators of cell cycle progression. By inhibiting these kinases, palbociclib can limit the cellular context in which C12orf59 operates, possibly reducing its activity by constraining the cell's progression through the cycle where C12orf59 might play a role. Trametinib, an inhibitor of MEK1/2, decreases ERK phosphorylation and activity, leading to a reduction in C12orf59 activity if it is associated with the MAPK/ERK pathway. Similarly, U0126 also targets MEK1/2, which can lead to a decrease in C12orf59 activity by impeding signaling through the ERK pathway. LY294002 and Wortmannin both target PI3K, which in turn diminishes AKT signaling and can decrease C12orf59 activity by disrupting the PI3K/AKT/mTOR pathway, a crucial signaling axis in various cellular processes.

Rapamycin directly inhibits mTOR and can reduce the activity of C12orf59 by affecting downstream signaling pathways that mTOR regulates, potentially altering the protein's functional landscape. Dasatinib disrupts Src family kinases and Bcr-Abl, leading to diminished C12orf59 activity if it relies on Src signaling for its function. Thapsigargin, a SERCA inhibitor, disrupts calcium homeostasis, which can alter cellular signaling and reduce C12orf59 activity by creating an environment that is unfavorable for its operation. Staurosporine, a broad-spectrum protein kinase inhibitor, can reduce C12orf59 activity by broadly inhibiting phosphorylation events that may be necessary for its function. SB203580 and SP600125 inhibit p38 MAPK and JNK, respectively, and can lead to a reduction in C12orf59 activity if it functions within these stress response pathways. Finally, Sunitinib, by inhibiting receptor tyrosine kinases, can affect signaling pathways that regulate C12orf59, thereby reducing its activity. Each chemical acts upon a specific signaling molecule or pathway that is known to influence C12orf59's activity, leading to a functional inhibition of the protein without affecting its expression or general protein translation.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Palbociclib

571190-30-2sc-507366
50 mg
$315.00
(0)

Inhibits CDK4/6 which are crucial for cell cycle progression, potentially reducing C12orf59 activity by limiting the cellular context in which it operates.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

Inhibits MEK1/2 leading to decreased ERK phosphorylation and activity, possibly reducing C12orf59 activity related to the MAPK/ERK pathway.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

Inhibits PI3K, affecting AKT signaling and potentially decreasing C12orf59 activity through this pathway.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Inhibits mTOR, potentially reducing the activity of C12orf59 by affecting downstream signaling pathways that mTOR regulates.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Inhibits Src family kinases and Bcr-Abl, potentially diminishing C12orf59 activity if it's reliant on Src signaling.

Thapsigargin

67526-95-8sc-24017
sc-24017A
1 mg
5 mg
$94.00
$349.00
114
(2)

Inhibits sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), disrupting calcium homeostasis, which could reduce C12orf59 activity by altering cellular signaling.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

Non-selective protein kinase inhibitor that could reduce C12orf59 activity by broadly inhibiting phosphorylation events necessary for its function.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

Inhibits MEK1/2, potentially leading to decreased activity of C12orf59 by impeding ERK pathway signaling.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Inhibits PI3K, which could lead to a reduction in C12orf59 activity by affecting the AKT/mTOR pathway.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

Inhibits p38 MAPK, potentially diminishing C12orf59 activity related to stress response pathways.